Search company, investor...

Predict your next investment

Venture Capital
bvflp.com

Investments

116

Portfolio Exits

48

Partners & Customers

1

About BVF Partners

BVF Partners is a private investment partnership specializing in fundamentally-driven public biotechnology investments.

Headquarters Location

One Sansome Street 30th Floor

San Francisco, California, 94104,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest BVF Partners News

Aro Biotherapeutics Secures $41.5M Series B Financing

Nov 28, 2023

PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with

BVF Partners Investments

116 Investments

BVF Partners has made 116 investments. Their latest investment was in Forward Therapeutics as part of their Series A on November 11, 2023.

CBI Logo

BVF Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/8/2023

Series A

Forward Therapeutics

$50M

Yes

OrbiMed Advisors, RA Capital Management, and Undisclosed Investors

4

10/5/2023

PIPE

SAB Biotherapeutics

Yes

2

9/6/2023

Series G

Nimbus Therapeutics

$210M

No

2

9/5/2023

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

8/2/2023

Series F

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2023

10/5/2023

9/6/2023

9/5/2023

8/2/2023

Round

Series A

PIPE

Series G

PIPE

Series F

Company

Forward Therapeutics

SAB Biotherapeutics

Nimbus Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$50M

$210M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

OrbiMed Advisors, RA Capital Management, and Undisclosed Investors

Sources

4

2

2

10

10

BVF Partners Portfolio Exits

48 Portfolio Exits

BVF Partners has 48 portfolio exits. Their latest portfolio exit was CTI BioPharma on June 26, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/26/2023

Acq - P2P

$99M

6

3/6/2023

Acq - P2P

$99M

4

2/3/2023

IPO

$99M

Public

23

11/22/2022

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/26/2023

3/6/2023

2/3/2023

11/22/2022

9/28/2022

Exit

Acq - P2P

Acq - P2P

IPO

Reverse Merger

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

4

23

10

10

BVF Partners Partners & Customers

1 Partners and customers

BVF Partners has 1 strategic partners and customers. BVF Partners recently partnered with Ligand Pharmaceuticals on May 5, 2010.

Date

Type

Business Partner

Country

News Snippet

Sources

5/21/2010

Partner

United States

Download this Press Release (). Ligand - Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma

As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally .

1

Date

5/21/2010

Type

Partner

Business Partner

Country

United States

News Snippet

Download this Press Release (). Ligand - Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma

As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally .

Sources

1

BVF Partners Team

3 Team Members

BVF Partners has 3 team members, including , .

Name

Work History

Title

Status

Mark Lampert

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Mark Lampert

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.